Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PRTC PureTech Health	$18.45 -0.8%	$17.92	$13.30 ▼ $25.00	$446.87M	1.11	4,907 shs	3,751 shs
SANA Sana Biotechnology	$4.45 +2.8%	$2.72	$1.26 ▼ $7.30	$976.31M	1.86	3.91 million shs	4.19 million shs
STOK Stoke Therapeutics	$12.35 +3.8%	$10.89	$5.35 ▼ $16.15	$649.70M	1.14	674,712 shs	465,985 shs
TNXP Tonix Pharmaceuticals	$47.19 +4.7%	$34.63	$6.76 ▼ $130.00	$331.52M	2.05	994,160 shs	2.24 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PRTC PureTech Health	+5.27%	+3.51%	-4.44%	+9.78%	-19.89%
SANA Sana Biotechnology	+3.59%	+6.91%	+71.83%	+162.42%	-36.88%
STOK Stoke Therapeutics	+1.28%	-1.00%	+1.71%	+54.75%	-19.27%
TNXP Tonix Pharmaceuticals	+1.95%	+17.47%	+21.88%	+186.82%	-26.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PRTC PureTech Health	2.4847 of 5 stars	3.8	5.0	0.0	1.8	0.0	0.0
SANA Sana Biotechnology	3.2697 of 5 stars	3.5	3.0	0.0	2.7	3.3	0.6
STOK Stoke Therapeutics	4.1598 of 5 stars	3.7	1.0	4.8	2.5	0.8	1.3
TNXP Tonix Pharmaceuticals	2.5416 of 5 stars	3.5	2.0	0.0	1.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PRTC PureTech Health	3.50	Strong Buy	$45.00	143.85% Upside
SANA Sana Biotechnology	3.00	Buy	$9.17	105.99% Upside
STOK Stoke Therapeutics	3.33	Buy	$24.75	100.40% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,139.67% Upside

Current Analyst Ratings Breakdown

Latest TNXP, STOK, PRTC, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PRTC PureTech Health	$4.32M	102.75	$2.37 per share	7.80	$17.04 per share	1.08
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A
STOK Stoke Therapeutics	$36.56M	18.44	N/A	N/A	$4.32 per share	2.86
TNXP Tonix Pharmaceuticals	$10.09M	34.42	N/A	N/A	$31.82 per share	1.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/30/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	15.63	N/A	N/A	26.33%	19.08%	15.72%	8/6/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)

Latest TNXP, STOK, PRTC, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	STOK Stoke Therapeutics	-$0.0905	N/A	N/A	N/A	$31.51 million	N/A
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PRTC PureTech Health	N/A	9.33	9.33
SANA Sana Biotechnology	N/A	3.40	3.40
STOK Stoke Therapeutics	N/A	8.41	8.41
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PRTC PureTech Health	0.04%
SANA Sana Biotechnology	88.23%
STOK Stoke Therapeutics	N/A
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
PRTC PureTech Health	5.30%
SANA Sana Biotechnology	30.10%
STOK Stoke Therapeutics	9.50%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PRTC PureTech Health	100	24.03 million	22.75 million	Not Optionable
SANA Sana Biotechnology	380	225.48 million	157.61 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable

TNXP, STOK, PRTC, and SANA Headlines

Recent News About These Companies

Tonix Pharma Plans Sales Force for TNX-102 SL

July 16 at 7:52 AM | tipranks.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.8% - Time to Sell?

July 11, 2025 | marketbeat.com

Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results

July 10, 2025 | msn.com

Tonix up after peer reviewed data for pain therapy and new data for mpox vaccine

July 10, 2025 | msn.com

Tonix Pharmaceuticals (TNXP) Surges 10% on Phase 3 Data Release

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.4% - Should You Buy?

July 10, 2025 | marketbeat.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...

July 10, 2025 | gurufocus.com

Tonix Pharmaceuticals (TNXP) Unveils Promising TNX-801 Vaccine Data | TNXP Stock News

July 10, 2025 | gurufocus.com

Tonix Pharma Unveils Promising TNX-801 Vaccine Findings

July 10, 2025 | tipranks.com

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

July 10, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.5% Higher - Here's Why

July 9, 2025 | marketbeat.com

Tonix Pharma Publishes Phase 3 Trial Results

July 9, 2025 | tipranks.com

Tonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia Management

July 9, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

July 9, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Here's Why

July 7, 2025 | marketbeat.com

Tonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against Monkeypox

July 7, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

July 7, 2025 | globenewswire.com

TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha

July 4, 2025 | seekingalpha.com

Tonix Pharmaceuticals' Combination Therapy of mTNX-1700 and Anti-PD1 Antibody Shows Promising Results in Gastric Cancer Models

July 2, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

July 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, STOK, PRTC, and SANA Company Descriptions

PureTech Health NASDAQ:PRTC

$18.37 -0.23 (-1.23%)

As of 04:00 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$4.45 +0.12 (+2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$4.49 +0.04 (+0.99%)

As of 07:59 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Stoke Therapeutics NASDAQ:STOK

$12.35 +0.45 (+3.78%)

Closing price 04:00 PM Eastern

Extended Trading

$12.34 -0.01 (-0.08%)

As of 06:26 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Tonix Pharmaceuticals NASDAQ:TNXP

$47.19 +2.13 (+4.73%)

Closing price 04:00 PM Eastern

Extended Trading

$47.94 +0.75 (+1.59%)

As of 07:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time